{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:32Z","timestamp":1793726072954,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1208\/s12249-019-1377-0","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T19:41:49Z","timestamp":1555443709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma"],"prefix":"10.1208","volume":"20","author":[{"given":"Usir S.","family":"Younis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Vallorz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie G.","family":"Ledford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Myrdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"1377_CR1","unstructured":"Asthma\u2019s impact on the nation: data from the CDC National Asthma Control Program. Center for Disease Control (CDC) and Prevention, Atlanta. 2012. \n                    http:\/\/www.cdc.gov\/asthma\/impacts_nation\/asthmafactsheet.pdf\n                    \n                  . Accessed 13 Feb 2015."},{"key":"1377_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1517\/13543784.9.1.25","volume":"9","author":"S Bryan","year":"2000","unstructured":"Bryan S, Leckie M, Hansel T, Barnes P. Novel therapy for asthma. Expert Opin Investig Drugs. 2000;9:25\u201342.","journal-title":"Expert Opin Investig Drugs"},{"key":"1377_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1164\/ajrccm.161.5.9903102","volume":"161","author":"J Bousquet","year":"2000","unstructured":"Bousquet J, Jeffrey P, Busse W, Johnson M, Vignola A. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720\u201345.","journal-title":"Am J Respir Crit Care Med"},{"key":"1377_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1164\/rccm.200203-191OC","volume":"166","author":"NJ Vanacker","year":"2002","unstructured":"Vanacker NJ, Palmans E, Pauwels RA, Kips JC. Effect of combining salmeterol and fluticasone on the progression of airway remodeling. Am J Respir Crit Care Med. 2002;166:1128\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"1377_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pupt.2012.08.008","volume":"26","author":"S Siddiqui","year":"2013","unstructured":"Siddiqui S, Redhu N, Ojo O, Liu B, Irechukwu N, et al. Emerging airway smooth muscle targets to treat asthma. Pulm Pharmacol Ther. 2013;26:132\u201344.","journal-title":"Pulm Pharmacol Ther"},{"key":"1377_CR6","doi-asserted-by":"crossref","unstructured":"Lam J, Levine S. The role of tyrosine kinases in the pathogenesis and treatment of lung disease, advances in protein kinases. In: Biochemistry, genetics and molecular biology. Rijeka, 2012. p. 181\u2013212.","DOI":"10.5772\/37901"},{"key":"1377_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/thorax.57.4.309","volume":"57","author":"C Ward","year":"2002","unstructured":"Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002;57:309\u201316.","journal-title":"Thorax."},{"key":"1377_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1183\/09031936.02.02562001","volume":"20","author":"NJ Vanacker","year":"2002","unstructured":"Vanacker NJ, Palmans E, Pauwels RA, Kips JC. Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats. Eur Respir J. 2002;20:873\u20139.","journal-title":"Eur Respir J"},{"key":"1377_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1164\/ajrccm.163.3.2004160","volume":"163","author":"NJ Vanacker","year":"2001","unstructured":"Vanacker NJ, Palmans E, Kips JC, Pauwels RA. Fluticasone inhibits but does not reverse allergen-induced structural airway changes. Am J Respir Crit Care Med. 2001;163:674\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1377_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","volume":"12","author":"A Kontzias","year":"2012","unstructured":"Kontzias A, Kotlyar A, Laurence A, Changelian P, O\u2019Shea J. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12:464\u201370.","journal-title":"Curr Opin Pharmacol"},{"key":"1377_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.183.1.1","volume":"183","author":"J Drazen","year":"1996","unstructured":"Drazen J, Arm J, Austen K. Sorting out the cytokines of asthma. J Exp Med. 1996;183:1\u20135.","journal-title":"J Exp Med"},{"key":"1377_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1183\/09031936.01.00229601","volume":"18","author":"J Kips","year":"2001","unstructured":"Kips J. Cytokines in asthma. Eur Respir J. 2001;18:24\u201333.","journal-title":"Eur Respir J"},{"key":"1377_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/thx.54.9.825","volume":"54","author":"K Chung","year":"1999","unstructured":"Chung K, Barnes P. Cytokines in asthma. Thorax. 1999;54:825\u201357.","journal-title":"Thorax."},{"key":"1377_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.coph.2005.01.009","volume":"5","author":"WS Wong","year":"2005","unstructured":"Wong WS. Inhibitors of the tyrosine kinase signaling cascade for asthma. Curr Opin Pharmacol. 2005;5:264\u201371.","journal-title":"Curr Opin Pharmacol"},{"key":"1377_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/ni.2617","volume":"14","author":"P Licona-Limon","year":"2013","unstructured":"Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14:536\u201342.","journal-title":"Nat Immunol"},{"key":"1377_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","volume":"101","author":"C Blanchard","year":"2009","unstructured":"Blanchard C, Rothenburg ME. Biology of the eosinophil. Adv Immunol. 2009;101:81\u2013121.","journal-title":"Adv Immunol"},{"key":"1377_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri3341","volume":"13","author":"HF Rosenberg","year":"2013","unstructured":"Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13:9\u201322.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1377_CR18","first-page":"553","volume":"9","author":"ABC Dy","year":"2018","unstructured":"Dy ABC, Tanyaratsrisakul S, Voelker DR, Ledford JG. The emerging roles of surfactant protein-A in asthma. J Clin Cell Immunol. 2018;9(4):553\u201368.","journal-title":"J Clin Cell Immunol"},{"key":"1377_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.intimp.2010.04.014","volume":"10","author":"R Malaviya","year":"2010","unstructured":"Malaviya R, Laskin D, Malaviya R. Janus kinase-3 dependent inflammatory responses in allergic asthma. Int Immunopharmacol. 2010;10:829\u201336.","journal-title":"Int Immunopharmacol"},{"key":"1377_CR20","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaci.2013.10.036","volume":"133","author":"S Ashino","year":"2014","unstructured":"Ashino S, Takeda K, Li H, Taylor V, Joetham A, Pine PR, et al. Janus kinase 1\/3 signaling pathways are key initiators of Th2 differentiation and lung allergic responses. J Allergy Clin Immunol. 2014;133:1162\u201374.","journal-title":"J Allergy Clin Immunol"},{"key":"1377_CR21","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","volume":"360","author":"RH Green","year":"2002","unstructured":"Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet. 2002;360:1715\u201321.","journal-title":"Lancet"},{"key":"1377_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.chemphyslip.2014.09.002","volume":"185","author":"E Parra","year":"2015","unstructured":"Parra E, Perez-Gil J. Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films. Chem Phys Lipids. 2015;185:153\u201375.","journal-title":"Chem Phys Lipids"},{"key":"1377_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nri1528","volume":"5","author":"JR Wright","year":"2005","unstructured":"Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5:58\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1377_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1586\/eci.11.27","volume":"7","author":"JP Abonia","year":"2011","unstructured":"Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011;7(4):411\u20137.","journal-title":"Expert Rev Clin Immunol"},{"key":"1377_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/DDDT.S155307","volume":"12","author":"C Pelaia","year":"2018","unstructured":"Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des Dev Ther. 2018;12:619\u201328.","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"1377_CR26","first-page":"564","volume":"42","author":"S Hom","year":"2017","unstructured":"Hom S, Pisano M. Reslizumab (Cinqair): an interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. Pharm Ther. 2017;42(9):564\u20138.","journal-title":"Pharm Ther"},{"key":"1377_CR27","unstructured":"Bethesda (MD): U.S. National Library of Medicine; 2018- Study of tofacitinib in refractory dermatomyositis; [about 1p.]. Available from: \n                    http:\/\/clinicaltrials.gov\/\n                    \n                  . \n                    ClinicalTrials.gov\n                    \n                   Identifier: NCT03002649. Accessed 22 Aug 2018."},{"key":"1377_CR28","unstructured":"Bethesda (MD): U.S. National Library of Medicine; 2017- Tofacitinib for the treatment of alopecia areata and its variants; [about 1p.]. Available from: \n                    http:\/\/clinicaltrials.gov\/\n                    \n                  . \n                    ClinicalTrials.gov\n                    \n                   Identifier: NCT02312882. Accessed 22 Aug 2018."},{"key":"1377_CR29","unstructured":"Bethesda (MD): U.S. National Library of Medicine; Evaluation of tofacitinib in early diffuse cutaneous system sclerosis (dcSSc) (TOFA-SSc); [about 1p.]. Available from: \n                    http:\/\/clinicaltrials.gov\/\n                    \n                  . \n                    ClinicalTrials.gov\n                    \n                   Identifier: NCT03274076. Accessed 22 Aug 2018."},{"key":"1377_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejphar.2007.12.024","volume":"582","author":"E Kudlacz","year":"2008","unstructured":"Kudlacz E, Conklyn M, Andersen C, Whitney-Pickett C, Changelian P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol. 2008;582:154\u201361.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1377_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1748-1716.1946.tb00349.x","volume":"11","author":"S Ostling","year":"1946","unstructured":"Ostling S, Virtama P. A modified preparation of the universal buffer described by Teorell and Stenhagen. Acta Physiol. 1946;11(4):289\u201393.","journal-title":"Acta Physiol"},{"key":"1377_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1208\/s12249-009-9371-6","volume":"11","author":"KL Karlage","year":"2010","unstructured":"Karlage KL, Mogalian E, Jensen A, Myrdal PB. Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A\/J mouse model. AAPS PharmSciTech. 2010;11:168\u201373.","journal-title":"AAPS PharmSciTech"},{"key":"1377_CR33","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/08958370802207318","volume":"20","author":"DJ Alexander","year":"2008","unstructured":"Alexander DJ, Collins CJ, Coombs DW, Gilkison IS, Hardy CJ, Healey G, et al. Association of inhalation toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 2008;20:1179\u201389.","journal-title":"Inhal Toxicol"},{"issue":"1\u20132","key":"1377_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijpharm.2004.08.005","volume":"286","author":"SG Machatha","year":"2004","unstructured":"Machatha SG, Yalkowsky SH. Estimation of the ethanol\/water solubility profile from the octanol\/water partition coefficient. Int J Pharm. 2004;286(1\u20132):111\u20135.","journal-title":"Int J Pharm"},{"issue":"4","key":"1377_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jps.2600740410","volume":"74","author":"SH Yalkowsky","year":"1985","unstructured":"Yalkowsky SH, Rubino JT. Solubilization by cosolvents I: organic solutes in propylene glycol-water mixtures. J Pharm Sci. 1985;74(4):416\u201321.","journal-title":"J Pharm Sci"},{"key":"1377_CR36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/carcin\/bgl216","volume":"28","author":"PB Myrdal","year":"2007","unstructured":"Myrdal PB, Karlage K, Kuehl PJ, Angersbach BS, Merrill BA, Wightman PD. Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A\/J murine model when administered via nose-only inhalation. Carcinogenesis. 2007;28:957\u201361.","journal-title":"Carcinogenesis."},{"issue":"1","key":"1377_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/jamp.2008.0740","volume":"23","author":"J Montharu","year":"2010","unstructured":"Montharu J, Le Guellec S, Kittel B, Rabemampianina Y, Guillemain J, et al. Evaluation of lung tolerance of ethanol, propylene glycol, and sorbitan monooleate as solvents in medical aerosols. J Aerosol Med Pulm Drug Deliv. 2010;23(1):41\u20136.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1377_CR38","first-page":"1","volume":"7","author":"JG Ledford","year":"2012","unstructured":"Ledford JG, Mukherjee S, Kislan MM, Nugent JL, Hollingsworth JW, et al. Surfactant protein-A suppresses eosinophil-mediated killing of Mycoplasma pneumonia in allergic lungs. Public Libr Sci One. 2012;7:1\u201312.","journal-title":"Public Libr Sci One"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-019-1377-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T09:32:19Z","timestamp":1589880739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-019-1377-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1208\/s12249-019-1377-0","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"28 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"167"}}